Scilex Holding Company

NASDAQ:SCLX USA Drug Manufacturers - General
Market Cap
$59.29 Million
Market Cap Rank
#23474 Global
#8202 in USA
Share Price
$8.43
Change (1 day)
+1.81%
52-Week Range
$0.19 - $30.00
All Time High
$30.00
About

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve… Read more

Scilex Holding Company (SCLX) - Total Liabilities

Latest total liabilities as of September 2025: $455.60 Million USD

Based on the latest financial reports, Scilex Holding Company (SCLX) has total liabilities worth $455.60 Million USD as of September 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Scilex Holding Company - Total Liabilities Trend (2020–2024)

This chart illustrates how Scilex Holding Company's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Scilex Holding Company Competitors by Total Liabilities

The table below lists competitors of Scilex Holding Company ranked by their total liabilities.

Liability Composition Analysis (2020–2024)

This chart breaks down Scilex Holding Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.05 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -2.57 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.65 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Scilex Holding Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Scilex Holding Company (2020–2024)

The table below shows the annual total liabilities of Scilex Holding Company from 2020 to 2024.

Year Total Liabilities Change
2024-12-31 $285.59 Million +4.14%
2023-12-31 $274.25 Million +445.35%
2022-12-31 $50.29 Million -83.34%
2021-12-31 $301.81 Million +35.23%
2020-12-31 $223.19 Million --